Ege Ünı̇versı̇tesı̇ Hastanesı̇nde jinekolojik kanserlerin epidemiyolojik ve genel sağ kalım özellikleri
Abstract
Amaç: Ege Üniversitesi Hastanesinde (EÜH) jinekolojik kanser (JK) tanısı ile tedavileri yapılan olguların epidemiyolojik ve genel sağ kalım (GSK) özelliklerini istatistiksel açıdan değerlendirmektir.
Gereç ve Yöntem: EÜ Kanserle Savaş Araştırma ve Uygulama Merkezi (EÜKAM) tarafından 1992-2017 arası EÜH’de 8332 JK kaydı yapılmıştır. CANREG-4 programı ile kaydedilen veriler SPSS programına aktarılmıştır. İstatistik analizde Ki-kare yöntemi ve doğrusal modellemeler yapılmış ve p <0,05 anlamlı kabul edilmiştir.
Bulgular: JK’ler, EÜH Kanser Kayıt Sisteminde tüm olguların %7,1’ini, kadın olguların ise %15,1’ini kapsamaktadır. JK’nin %41,6’sı korpus uteri, %31,8’i serviks uteri, %21,3’ü ise over kanseri, %3,7’si vulva-vajina kanseri olarak saptanmıştır. Korpus uteri kanseri serviks uteri kanserine göre daha ileri yaşlarda görülmektedir (p<0,0001). Korpus uteri kanseri en sık 50-59 yaş grubunda (%35,9), serviks uteri kanseri 40-49 yaşlarda (%28,1), over kanseri ise 50-59 yaşlarda (%30,1) görülmektedir. Korpus uteri kanserinin görülüşünde yıllara göre doğrusal artış, serviks uteri kanserinde ise doğrusal azalma gözlenmektedir (p<0,0001). Korpus uteri kanserleri, serviks uteri ve over kanserlerine göre daha erken evrelerde tanı almaktadır (p<0,0001). Yerleşime göre en sık tanı; korpus uteri kanserinde %70 lokal evrede, serviks uteri kanserinde %47,2 lokal ileri evrede, over kanserinde %63,6 metastatik evrede olmaktadır.
Sonuç: EUH Kanser Kayıt Sisteminde JK’ler tüm sistemler arasında altıncı sıradadır. JK’nin içinde korpus uteri kanseri %41,6 ile ilk sırada yer almaktadır. Yıllar içinde görülme sıklığı açısından korpus uteri kanserinde doğrusal artış, serviks uteri kanserinde doğrusal azalma gözlenmektedir.
References
- Jemal A, Vineis P, Bray F, Torre L, Forman D (Editörler). Kanser Atlası. İkinci Baskı. Atlanta, GA: Amerikan Kanser Derneği; 2014. www.cancer.org/canceratlas.
- Bray F, Ferlay J, Soerjomataram I and et al: Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2018; 68: 394-424.
- Gültekı̇n M, Boztaş G; Türkı̇ye Kanser İstatı̇stı̇klerı̇. T.C. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, Kanser Savaş Daire Başkanlığı. 2016.
- Siegel RL, Miller KD, Jemal A.CA. Cancer Statistics, 2018. CA CANCER J CLIN 2018;68:7–30.
- Bray F, Ferlay J, Laversanne M et al: Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int. J. Cancer: 137, 2060–2071 (2015)
- Jemal A, Center MM et al: Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiol Biomarkers Prev; 19 (8); 1893–907. ©2010 AACR.
- Gültekin M, Dündar S et al: Survival of gynecological cancers in Turkey: where are we at? J Gynecol Oncol. 2017 Nov; 28 (6): e85.
- Chen T, Jansen L, Gondos A, Ressing M, Holleczek B, Katalinic A, et al. Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. BMC Cancer 2012; 12: 128.
- Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2191-205.
- American Cancer Society. Cancer facts & figures 2017 [Internet]. Atlanta, GA: American Cancer Society; 2017 [cited 2017 Apr 10]. Available from: https://www.cancer.org/content/dam/cancer-org/research/ cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.
Epidemiological and overall survival characteristics of gynecologic cancers in Ege University Hospital database
Abstract
Aim: Aim of this study is to evaluate epidemiologic features and survival outcomes of patients treated with the diagnosis of gynecologic cancer (GC) in Ege University Hospital (EUH).
Materials and Methods: 8332 GC were recorded in EUH between 1992-2017 by EU Fight Against Cancer Research and Application Center (EUKAM). Data recorded by CANREG-4 program were transferred to SPSS program. For statistical analysis, Chi-square method and linear modeling were performed and p<0.05 was accepted as significant.
Results: GC was 7.1% of all cancer records and 15.1% of women cancers in EU. 41.6% of GC was uterine cancer, 31.8% was cervical cancer and 21.3% was ovarian cancer, and 3.7% was vulva-vaginal cancer. Uterine cancer was detected more in elder patients than cervical cancer (p<0.0001). Uterine cancer was mostly seen between 50-59 ages (35.9%), cervical cancer between 40-49 ages (28.1%) and ovarian cancer was seen mostly between 50-59 ages (30.1%).
Incidence of uterine cancer increased gradually with increasing age, but cervical cancer incidence decreased by increasing age (p<0.0001). Uterine cancer was detected in early stages according to cervical and ovarian cancer (p<0.0001). Uterine cancer was mostly seen locally (70%), cervical cancer was mostly seen in local advanced stage (47.2%) and ovarian cancer was mostly seen at metastatic stage (63.6%).
Discussion: GC was the sixth most common cause of cancer in EUH cancer record system. Uterine cancer is most common GC with the rate of 41.6%. Incidence of uterine cancer increased gradually with increasing age while cervical cancer incidence decreased..
References
- Jemal A, Vineis P, Bray F, Torre L, Forman D (Editörler). Kanser Atlası. İkinci Baskı. Atlanta, GA: Amerikan Kanser Derneği; 2014. www.cancer.org/canceratlas.
- Bray F, Ferlay J, Soerjomataram I and et al: Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2018; 68: 394-424.
- Gültekı̇n M, Boztaş G; Türkı̇ye Kanser İstatı̇stı̇klerı̇. T.C. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, Kanser Savaş Daire Başkanlığı. 2016.
- Siegel RL, Miller KD, Jemal A.CA. Cancer Statistics, 2018. CA CANCER J CLIN 2018;68:7–30.
- Bray F, Ferlay J, Laversanne M et al: Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int. J. Cancer: 137, 2060–2071 (2015)
- Jemal A, Center MM et al: Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiol Biomarkers Prev; 19 (8); 1893–907. ©2010 AACR.
- Gültekin M, Dündar S et al: Survival of gynecological cancers in Turkey: where are we at? J Gynecol Oncol. 2017 Nov; 28 (6): e85.
- Chen T, Jansen L, Gondos A, Ressing M, Holleczek B, Katalinic A, et al. Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage. BMC Cancer 2012; 12: 128.
- Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2191-205.
- American Cancer Society. Cancer facts & figures 2017 [Internet]. Atlanta, GA: American Cancer Society; 2017 [cited 2017 Apr 10]. Available from: https://www.cancer.org/content/dam/cancer-org/research/ cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Supplement |
| Authors | |
| Publication Date | December 31, 2019 |
| Submission Date | February 15, 2019 |
| Published in Issue | Year 2019 |
Cited By
Batı Marmara Bölgesindeki Bir Üniversite Hastanesinde Son Üç Yıllık Dönemdeki Jinekolojik Malignite Vakalarının Retrospektif Analizi
Online Türk Sağlık Bilimleri Dergisi
Sevde AKSU
https://doi.org/10.26453/otjhs.842600